By Park Soo-nam, Reporter
CEO Yoon Woong-seop's Background and Leadership Style
Born in 1967, Yoon Woong-seop is the grandson of IlDong’s late founder, Yoon Yong-gu, and the eldest son of current Chairman Yoon Won-young. He graduated from Yonsei University with a degree in Applied Statistics and earned a master’s in Accounting from Georgia State University in the U.S. He began his career as an accountant at KPMG International. Yoon joined IlDong Pharmaceutical in 2005 as a managing director and climbed the ranks through roles such as PI Team Leader, Head of Planning and Coordination, Executive Director, and Vice President. He was appointed Co-CEO in 2014 and has been overseeing management as Vice Chairman since 2021.
Known for his calm demeanor and emphasis on working-level personnel, Yoon prioritizes clarity in goal-setting to ensure strong execution. Mirroring the founder’s character, he maintains communication with employees while pushing forward a restructuring process that tolerates short-term losses in exchange for aggressive R&D investment. Instead of replacing top executives, he retains trusted figures within the founding family to ensure organizational continuity.
Strategic Direction Since Yoon’s Appointment
Since taking the helm, Yoon has directed IlDong toward three major strategic pillars:
◆ Strengthening R&D and open innovation
◆ Expanding into global markets
◆ Enhancing core businesses (ETC, OTC, CHC) and improving cost-efficiency
1. Focused R&D Investment and Open Innovation
Yoon raised the company’s R&D investment to about 20% of total sales—one of the highest in the industry. Over four years, approximately KRW 400 billion has been poured into R&D. IlDong collaborates closely with its subsidiaries—iReePharm (compound discovery), Ames Bioscience (clinical pharmacology consulting), and iDience (drug development and commercialization)—to secure promising drug candidates. Through open innovation, IlDong actively sources and co-develops external candidates from universities and research institutes. It also seeks global patent protections for key pipelines.
2. Global Expansion and Licensing Strategy
To enter global markets, IlDong is expanding licensing deals and overseas partnerships. The company registers patents for its drug candidates in regions like the U.S., Europe, and Japan and is actively pursuing co-development and licensing-out of new drugs. For instance, clinical trials and patent applications for its diabetes and NASH candidates (IDG16177, ID119031166) are underway in the U.S., Europe, and China. A dedicated "Scientific Licensing Group" within the Global Business Division oversees technology export efforts, bringing in experts to facilitate early-stage licensing.
3. Strengthening Core Businesses and Cost Efficiency
While investing in innovation, IlDong also aims to grow its traditional segments—prescription drugs (ETC), over-the-counter products (OTC), and consumer healthcare (CHC)—by boosting marketing and investments. In shareholder meetings, Yoon emphasized enhancing profitability through targeted investment in these areas. To offset rising R&D costs, IlDong streamlined its workforce, optimized R&D and marketing expenses, and spun off its R&D unit, Unovia, to separate related costs and improve financials.
Execution Examples and Results
1. R&D Outcomes
Key success stories include the development of new candidates for diabetes, obesity, and liver diseases. For example, IDG16177 (a GPR40 agonist for diabetes) received Phase 1 approval from Germany’s BfArM and is currently in clinical trials. Other candidates like ID110521156 (oral obesity drug) and ID119031166 (NASH treatment) are progressing well. Global patent coverage has been secured across the U.S., Japan, Australia, Europe, and China, paving the way for commercialization and technology transfer. Despite rising costs from launching Unovia, the expanded pipeline lays a strong foundation for long-term growth.
2. Licensing-Out and Partnerships
IlDong mitigates risk and generates revenue by licensing out promising compounds. In May 2024, Unovia signed a co-development and licensing deal with Daewon Pharmaceutical for P-CAB (a novel treatment for GERD), granting domestic development and marketing rights to Daewon. Unovia will receive upfront payments and royalties upon commercialization. This example showcases IlDong's strategy of monetizing assets through licensing, enabling recovery of R&D costs.
3. Revenue and Profit Changes
From 2016 to 2022, IlDong’s annual revenue rose steadily from KRW 479.9 billion to KRW 637.7 billion. However, rising R&D costs led to operating losses from 2021. In 2022, despite a 14% revenue increase, IlDong posted a KRW 73.5 billion operating loss. The trend continued into 2023 with sales of KRW 600.8 billion and a KRW 53.9 billion operating deficit. However, structural reforms and Unovia’s spin-off led to a rebound in Q4 2023, achieving KRW 9.3 billion in net profit under separate financials. Cost efficiency and renewed marketing are starting to stabilize profitability.
4. Market Position and Pipeline
Core products are strengthening market share. Moisturizer “Careleaves” is the No.1 bandage brand in Korean pharmacies, while long-standing brands like “Aronamin” (vitamins) and “GQ Lab” (probiotics) continue to grow. IlDong’s subsidiaries, including Unovia and iDience, manage over 10 drug candidates (e.g., diabetes, NASH, liver, GI, and ophthalmic diseases), further expanding the company’s pipeline through open collaboration and external technology acquisition.
Future Growth Outlook and Strategic Forecast
Yoon’s aggressive R&D investments are expected to drive future growth. While profitability has suffered in the short term, cost restructuring and product realignment could trigger a rebound. Commercialization of drug candidates will be the key variable. If successful, drugs like IDG16177, ID110521156, and ID119031166 could significantly boost revenue and operating income. Achieving Yoon’s long-term goal of KRW 1 trillion in sales and KRW 100 billion in profit hinges on these outcomes. Meanwhile, licensing-out to multinationals ensures near-term cash flow and funds further investment. Global innovation sourcing via open innovation is also likely to increase.
IlDong has stated its dual focus on “new drug development and profitability” and aims to strike a balance between R&D and financial performance.
Strategic Validity via Industry and Competitor Comparison
IlDong’s strategy is rare in Korea’s pharma sector, where most mid-sized companies focus on generics, licensing-in, and incremental product improvements, typically spending less than 10% of revenue on R&D. IlDong, however, invests about 20%, mirroring leading global players. Industry experts view this as a high-stakes play to become a drug development powerhouse.
Globally, pharma companies invest 15–20% of sales in R&D, and licensing-out is a standard model for monetizing innovation—already adopted by several Korean firms. While many competitors rely more on joint research or licensing-in, IlDong’s focus on proprietary pipeline development could give it a competitive edge.
From an investor’s standpoint, IlDong’s aggressive strategy carries both high risk and high reward. Previous operating losses were side effects of its R&D focus. But successful commercialization could propel it into the top tier of Korean pharma companies within five years. However, failure could lead to significant losses, so investors must evaluate execution risks and long-term cash flow projections carefully.
Overall, IlDong’s strategy aligns well with pharma-biotech industry trends (e.g., new drug focus, licensing) and holds strong long-term value creation potential. Investors may view the high R&D intensity and market-driven outcomes as credible indicators of future success.
Conclusion
Since Yoon Woong-seop took over, IlDong Pharmaceutical has restructured its strategy around bold R&D investment, global market penetration, and core business reinforcement. With a high R&D-to-sales ratio (~20%) and a robust open innovation framework, IlDong has built a diverse pipeline and taken steps to enhance profitability through Unovia’s spin-off and dedicated licensing structures. If new drug development efforts pay off, reaching KRW 1 trillion in sales may be well within reach. Investors should consider the company’s departure from traditional paradigms and high-risk, high-return profile. Backed by a strong pipeline and improving financials, IlDong appears well-positioned for sustainable growth, and its strategy is validated by its industry-leading R&D ratio and market-aligned results.
Copyright ⓒ CEONEWS 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
